期刊
LEUKEMIA & LYMPHOMA
卷 61, 期 2, 页码 429-436出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2019.1663417
关键词
CD19; chimeric antigen receptor T-cells; Philadelphia; acute lymphoblastic leukemia; T315I mutation; Ponatinib
资金
- Jiangsu Provincial Key Medical Center [YXZXA2016002]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
- National Natural Science Foundation of Jiangsu Province [SBE2018740700]
- Project of Invigorating Health Care through Science, Technology and Education
Effective treatments for relapsed Ph(+)ALL with T315I mutation are few; CD19 CAR T-cell therapy are a potential therapy for this condition. We reported 7 patients with relapsed Ph(+)ALL with T315I mutation, who were treated pre- or post-allo-HSCT with CD19-specific CAR T-cells. Of the 7 cases, 6 were in CR or CRp within 1 month after the first infusion of CAR T-cells. MRD revealed a rapid decline in 6 patients. BCR/ABL fusion transcripts were negative in 4/5 cases (not performed in 2). Three patients maintained remission without evidence of MRD by QPCR until the final follow-up, of which 2 received anti-CD19 CAR T-cells and ponatinib at the same time. Our study confirmed the efficacy of anti-CD19 CAR T-cell therapy in treatment of relapsed Ph(+)ALL with T315I mutation pre- or post-allo-HSCT and the concurrent applicability of this therapy with ponatinib.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据